# Will a KFF poll published between 1 January and 31 December 2027 report that at least 20% of US adults have ever taken a GLP-1 drug?

> As of 17 November 2026, Prolepsia puts the chance of yes at 78%.

- Forecaster: Prolepsia (https://prolepsia.com)
- Forecast made: 2026-11-17
- Question type: Yes / no
- Resolves: 2028-01-01
- Status: Open
- Forecasts: 1
- Page: https://prolepsia.com/forecasts/augur-epsilon-compass/will-a-kff-poll-published-between-1-january-and-31-december-2027-report-that-at
- Open in the app: https://app.prolepsia.com/library/59bb6f4b-ced3-4237-93d9-a72a7399d910

## Forecast

- Yes: 78%
- No: 22%

## How Prolepsia reasons

## TL;DR
The forecast is **77.8% Yes and 22.2% No**, as of November 17, 2026. The case for Yes rests on lifetime use already approaching the threshold and new access channels supporting first-time treatment. The decisive distinction is that KFF must publish a new qualifying finding during 2027; actual prevalence alone does not resolve the question.

## Context
The question concerns lifetime GLP-1 use among all U.S. adults, including current and former users and all reasons for treatment. It does not concern current use alone, weight-loss use alone, or use among patients with a particular condition. At least one new qualifying KFF finding must first appear between January 1 and December 31, 2027.

The latest verified KFF observation is 18% lifetime use from March 2026. That is a fresh survey result, not simply a summary of older polling ([March topline](https://files.kff.org/attachment/topline-kff-health-tracking-poll-march-2026.pdf)). No later qualifying measurement has been established as of the forecast date. That does not prove none exists. The evidence supports further uptake, but leaves uncertainty about both its pace and KFF’s publication calendar.

## Evidence
The historical backbone is short but directly relevant. KFF has three verified, comparable survey waves. Their full history shows a large initial increase followed by an unchanged reading, rather than an uninterrupted rise.

| KFF survey | Adult sample | Ever used | Currently using | Former users |
|---|---:|---:|---:|---:|
| May 2024 | 1,479 | 12% | 6% | 6% |
| November 2025 | 1,350 | 18% | 12% | 6% |
| March 2026 | 1,343 | 18% | 12% | 6% |

The original reports and comparative topline document these observations ([May 2024 report](https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/); [November 2025 report](https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/); [March 2026 topline](https://files.kff.org/attachment/topline-kff-health-tracking-poll-march-2026.pdf)). The March survey was fielded February 24–March 2 among a nationally representative sample and reported a maximum full-sample sampling margin of ±3 percentage points. Its lifetime figure comprises 12% current and 6% former users ([methodology and results](https://files.kff.org/attachment/topline-kff-health-tracking-poll-march-2026.pdf)).

This history favors Yes because the latest estimate is close to the threshold and the earlier increase was substantial. It does not establish a dependable annual growth rate. The unchanged November and March estimates are a genuine counterweight. They can reflect slower adoption, survey variation, or both. The slightly different May question wording also limits precision in comparisons across the series ([comparative questionnaire](https://files.kff.org/attachment/topline-kff-health-tracking-poll-march-2026.pdf)).

Publication history is less reassuring than the calendar-year pattern first appears. There was a qualifying observation in each year from 2024 through 2026, but roughly 18 months separated the first two surveys. That is not a fixed annual schedule. KFF’s March 31 monitoring statement expresses an intention to keep following public experiences with these medications, not a commitment to ask the lifetime-use question during 2027 ([KFF overview](https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices/)). Continued monitoring supports the forecast, while leaving publication risk intact.

Other surveys support broad adoption but disagree on its measured level. Gallup’s weight-loss-specific series contains the following history:

| Gallup survey year | Ever used for weight loss | Currently using for weight loss |
|---|---:|---:|
| 2024 | 6% | 3% |
| 2025 | 12% | 8% |
| 2026 | 15% | 11% |

The latest survey covered 5,065 adults during May 28–June 5, 2026. The report was revised on September 8 after updated weighting ([Gallup report](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx)). The upward pattern supports continued uptake. Its narrower wording prevents direct substitution for KFF’s all-indication measure. Weight-loss and diabetes-use figures also cannot simply be added, because the populations can overlap.

NORC provides a caution in the other direction. Its February 19–23, 2026 survey of 1,073 adults found 14% lifetime use, comprising 9% current and 5% former use ([NORC report](https://www.norc.org/research/library/social-feeds-outpace-medical-advice-as-primary-source-for-glp-1-drug-information.html)). That is below KFF’s nearly contemporaneous result. The difference shows why KFF’s 18% should not be treated as an exact population baseline. Sampling, wording, and weighting are plausible explanations, but their individual contributions remain unresolved.

A recently published report can also contain older evidence. The CDC’s November 12, 2026 report found 9.8% past-year use using interviews conducted in July–August 2025 ([CDC report](https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm)). Past-year use is not lifetime use, and publication recency does not make those observations newer than KFF’s March fieldwork.

Oral medications provide a concrete route to additional first-time use. Truveta identified 182,101 adults initiating oral semaglutide during December 22, 2025–September 30, 2026. Among those with a preceding-year healthcare encounter, 41% had no recorded prior GLP-1 therapy ([Truveta analysis](https://www.truveta.com/blog/research/early-uptake-wegovy-pill-oct-2026-update/)). This supports expansion beyond existing users, but incomplete records prevent equating “no recorded prior therapy” with never having taken a GLP-1.

Manufacturer evidence points in the same direction but uses different definitions. Novo Nordisk reported 82% new-to-GLP-1 starts over January 9–May 15, 2026, using a 12-month prescription lookback that excluded compounded products ([manufacturer release](https://www.novonordisk-us.com/media/press-releases/wegovy-pill-surpasses-3-million-prescriptions.html)). That statistic is not directly comparable with Truveta’s. Neither establishes the number of lifetime first-time users across the adult population. The inference is positive but limited: oral options are attracting some additional users, not merely generating refills.

Medicare access supplies another positive driver. CMS launched the GLP-1 Bridge on July 1, 2026, with specified drugs available to eligible beneficiaries for $50 per month through December 31, 2027 ([CMS announcement](https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications)). Eligibility restrictions prevent treating this as universal Medicare coverage. CMS’s April 21 status update also states that Medicare BALANCE will not launch in 2027; the Bridge extension is the relevant expansion, not an additional BALANCE launch ([CMS status update](https://www.cms.gov/files/document/status-update-bridge-demo-balance-model-part-d-cy2027-g-pdf.pdf)).

Cost restrains these growth channels. KFF found affordability difficulties among 56% of current or former users in its November 2025 survey ([KFF report](https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/)). Its October 2026 employer findings describe limited weight-loss coverage and little intention among non-covering employers to add it ([employer survey release](https://www.kff.org/private-insurance/workers-now-pay-7471-on-average-annually-for-family-health-coverage-up-9-or-621-from-2025-benchmark-employer-health-benefits-survey-finds/)). These barriers can prevent new starts even when demand is strong.

## What's non-obvious
**Stopping treatment does not reverse lifetime use.** Affordability problems and discontinuation can weaken current-use figures without removing anyone from the ever-use category. Conversely, booming prescriptions or sales can overstate progress toward this question’s threshold if they mainly reflect refills or brand switching. The decisive medical quantity is first-time exposure, not treatment persistence or market revenue.

The other easily missed distinction is between prevalence and publication. A new poll first published during 2027 can qualify even if its fieldwork occurred earlier. A survey conducted during 2027 but first published in 2028 cannot. Multiple qualifying polls create more opportunities for a threshold-crossing result, but they are not independent evidence about underlying adoption. One qualifying point estimate is sufficient; it need not establish that true population prevalence exceeds the threshold with statistical confidence.

## Uncertainties
The largest distinct gap is KFF’s future schedule and questionnaire. Its monitoring statement supports continued attention but provides no confirmed qualifying publication date. A survey that reports only current use, a subgroup, or historical results does not satisfy the question. A confirmed publication plan containing the all-adult lifetime-use item would reduce this uncertainty most directly.

The next gap is nationally representative evidence on genuinely first-time users after March 2026. Commercial records often have limited lookback windows, while prescription totals include repeat use. A fresh KFF lifetime-use estimate would clarify whether the flat recent readings reflected a pause or survey noise. Better linked treatment histories would help distinguish new users from switchers, though they would still not replace the resolving KFF survey.

Finally, measurement and reporting matter near the boundary. Future estimates can fall below earlier readings because the samples and responses change. An explicitly reported 20% qualifies, while a controlling 19% topline does not, even if a headline says “about one in five.” An authoritative unrounded estimate takes precedence, and corrections available by January 31, 2028 govern the result. These uncertainties preserve meaningful room for No without changing the forecast’s clear lean toward Yes.

## Forecast history

| Date | Forecast |
|---|---|
| 2026-11-17 | 78% chance of yes |

## Sources Prolepsia read

- [KFF Health Tracking Poll - KFF Tracking Poll on Health Information and Trust - March 2026](https://files.kff.org/attachment/topline-kff-health-tracking-poll-march-2026.pdf)
- [KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs \| KFF](https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs)
- [In U.S., GLP-1 Usage Reaches New High](https://news.gallup.com/poll/712157/glp-usage-reaches-new-high.aspx)
- [Social Feeds Outpace Medical Advice as Primary Source for GLP-1 Drug Information \| NORC at the University of Chicago](https://www.norc.org/research/library/social-feeds-outpace-medical-advice-as-primary-source-for-glp-1-drug-information.html)
- [Use of Glucagon-Like Peptide-1 Medications and Modified Medication Use Among Adults — United States, 2025 \| MMWR](https://www.cdc.gov/mmwr/volumes/75/wr/mm7544a1.htm)
- [AMCP Nexus: Early uptake of oral semaglutide for obesity (Wegovy pill) \| Truveta](https://www.truveta.com/blog/research/early-uptake-wegovy-pill-oct-2026-update)
- [Wegovy® Pill Surpasses 3 Million Rx \| Novo Nordisk U.S.](https://www.novonordisk-us.com/media/press-releases/wegovy-pill-surpasses-3-million-prescriptions.html)
- [CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications \| CMS](https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications)
- [News Details](https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=919765)
- [Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio \| Eli Lilly and Company](https://investor.lilly.com/node/55191)

## The question

This question asks whether at least one poll published by KFF (formerly the Kaiser Family Foundation) between January 1, 2027, and December 31, 2027, inclusive, reports that 20% or more of U.S. adults aged 18 and older have ever taken a glucagon-like peptide-1 (GLP-1) medication. The measure includes respondents who currently take a GLP-1 medication and those who previously took one but have since stopped. It includes GLP-1 medications used for weight loss, diabetes management, or other medical conditions, regardless of the reason for use. Examples include Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Trulicity. The question concerns the percentage of all U.S. adults reporting lifetime use, rather than the percentage of adults currently using these medications or the percentage within a particular demographic subgroup. Background: KFF's May 2024 Health Tracking Poll found that 12% of U.S. adults reported ever taking a GLP-1 medication, including 6% who were currently taking one. By November 2025, KFF reported that 18% of adults had ever taken a GLP-1 medication, including 12% who were currently taking one. KFF's March 2026 polling continued to report an 18% lifetime-use figure. These findings indicate that the reported prevalence of lifetime GLP-1 use increased substantially between 2024 and 2025 and was approaching the 20% threshold before the forecast period. The question is whether any qualifying KFF poll published during calendar year 2027 reports lifetime use reaching or exceeding 20%. Sources: KFF Health Tracking Poll, May 2024 (https://www.kff.org/health-costs/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/); KFF Health Tracking Poll, November 2025 (https://www.kff.org/public-opinion/kff-health-tracking-poll-prescription-drug-costs-views-on-trump-administration-actions-and-glp-1-use/); KFF Public Opinion on Prescription Drugs and Their Prices, updated March 2026 (https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices/).

### How it resolves

The question resolves YES if at least one qualifying KFF poll is first published between January 1, 2027, and December 31, 2027, inclusive, and reports that at least 20% of U.S. adults have ever taken a GLP-1 medication. A qualifying poll must be conducted or commissioned by KFF, use a sample intended to be nationally representative of U.S. adults aged 18 and older, and report the percentage of all U.S. adults who have ever used GLP-1 medications. The relevant measure must include both current and former users. A reported percentage of exactly 20% qualifies. The reported point estimate determines the outcome, without adjustments for margins of error or statistical significance. The primary resolution source is KFF's official website (kff.org), including its Health Tracking Poll reports, public opinion research publications, accompanying methodology documents, and official survey toplines. If KFF publishes multiple qualifying polls during 2027, the question resolves YES if any one of them reports a qualifying percentage, even if other polls report lower percentages. The question resolves NO if at least one qualifying KFF poll is published during 2027 but none reports a lifetime-use percentage of at least 20%. If KFF publishes no qualifying poll during 2027, the question resolves NO because the specified publication event did not occur. Polls conducted in 2027 but first published in 2028 do not qualify. Polls conducted before 2027 but first published during 2027 qualify, provided they meet all other requirements. If a KFF report published during 2027 presents new results alongside historical comparisons, only results newly published in that report qualify; previously published historical estimates do not independently satisfy the condition. Resolution should occur after December 31, 2027, once the qualifying publications from that calendar year can be assessed. If the availability or contents of a qualifying publication cannot be established reliably through KFF's official records or archived copies, the question may be annulled if the evidence is insufficient to determine whether the publication condition was met.

### Fine print

Publication dates are determined using the dates displayed on KFF's official publications, interpreted according to U.S. Eastern Time where necessary. The percentage must refer to lifetime use among the entire adult U.S. population, not current use, use specifically for weight loss, or use within a subgroup such as adults with diabetes. Both prescription GLP-1 receptor agonists and medications commonly categorized by KFF as GLP-1 drugs, including dual GIP/GLP-1 receptor agonists such as tirzepatide, are included when KFF includes them in its survey question. The outcome is based on KFF's published survey results rather than an independent assessment of actual medication use. Self-reported use is sufficient, and no verification through medical or prescription records is required. If KFF reports an unrounded point estimate, that estimate takes precedence over rounded figures in accompanying headlines or narrative summaries. Otherwise, the percentage reported in KFF's official survey topline takes precedence over a rounded narrative description. For example, a topline figure of 19% does not qualify even if an accompanying headline describes the result as 'about one in five adults.' An explicitly reported figure of 20% does qualify. If a report published during 2027 is subsequently corrected, the corrected result will be used, provided the correction is available by January 31, 2028. A qualifying original report must still have been published within the 2027 window. Updates to older publications that merely repeat previously released survey findings do not count as new qualifying polls. The resolution concerns whether KFF publishes at least one qualifying finding, not whether the actual percentage of U.S. adults who have ever taken GLP-1 drugs reaches 20% during 2027.

---

Prolepsia’s forecasting engine made this forecast: it researched the question, weighed the evidence and wrote the report on this page. A probability is not a promise; this one changes as the evidence does.
